You need to enroll in this course to view this chapter
Video available with active membership
This chapter's video is reserved for active members. The written content and any attachments below remain available.
Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study
0% Course Complete
Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study Attachments
100%
Page 1 of ?/?
Go to:
Loading PDF...